AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04145466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-fat diet
Description: The high-fat diet will consist of \~40% energy from fat and \~45% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed
Study NCT04145466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Description: The high-carbohydrate diet will consist of \~20% of energy from fat and \~65% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed
Study NCT01573442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: 10.4 mg
Study NCT01573442 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01728402 — intervention group
Intervention type: PROCEDURE
Intervention: blood draw, bone marrow procedure, or tissue biopsy
Study NCT05110443 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: D-WB PET/CT
Description: Instead of the usual procedure of having the injection of the radiotracer in the waiting room and having to wait 60 minutes before being moved to the scanner room for imaging, the study participants will be injected with the radiotracer already laying on the scanner bed and the scan will commence immediately.~Therefore, in this study the patients are still only being scanned once, but we are gathering PET information in a different way.
Study NCT04175847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC88
Description: Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.~Phase IIa indication exploration
Study NCT03526835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-158
Description: full-length IgG1 bispecific antibody targeting EGFR and LGR5
Study NCT03526835 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MCLA-158 + Pembrolizumab
Description: MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.
Study NCT03526835 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MCLA-158 + FOLFIRI
Description: MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.
Study NCT03526835 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MCLA-158 + FOLFOX
Description: MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.
Study NCT01409161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Given IV
Study NCT00003783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT01409161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV
Study NCT01409161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01409161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: Given PO
Study NCT03047837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months
Study NCT03047837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET
Description: Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months
Study NCT03047837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm A (control arm) Treatment: placebo ASA + placebo MET Doses: 1 tablet daily +1 tablet twice a day (BID) Duration: 12 months
Study NCT04423029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF6002
Description: Specified dose on specified days
Study NCT00003783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study NCT00003783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00003783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00003783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00003783 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02213848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
Study NCT02213848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
Study NCT03006991 — intervention group
Intervention type: OTHER
Intervention: therapeutic drug monitoring
Description: dose of methotrexate can be adjusted by therapeutic drug monitoring.
Study NCT00711854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole (TMP-SMX)
Description: TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
Study NCT00711854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid (600 mg IV or PO twice daily)
Study NCT00711854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin (600 mg IV or PO once daily)
Study NCT00799240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A: Pemetrexed Cisplatin
Description: Pemetrexed: 500mg/m2 IV on day 1 and Cisplatin: 75 mg/m2 IV on day 1 every 21 days x 6 cycles.
Study NCT00799240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B Pemetrexed, Cisplatin and MK-0646
Description: Pemetrexed 500 mg/m2 IV on Day 1 and Cisplatin 75 mg/m2 IV on Day 1 every 21 days for 6 cycles in combination with MK-0646 will be given IV, 10 mg/KG, Days 1, 8 and 15 weekly.
Study NCT04423029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT04391894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECF843
Description: Topical ocular eye drop
Study NCT04391894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECF843 vehicle
Description: Topical ocular eye drop
Study NCT04391894 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ECF843 vehicle
Description: Topical ocular eye drop
Study NCT02584530 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance for PICC line placement
Description: Apply ultrasound guidance for PICC line placement and positioning in newborns
Study NCT00812006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
Study NCT00812006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
Study NCT04300517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Three sachet of protein supplement to be mixed in with water used daily
Description: Three sachet of protein supplement to be mixed in with water used daily
Study NCT01141855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Champix
Description: Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days~1mb b.d. for 70 days (full course 3 months)
Study NCT01141855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling alone
Description: Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
Study NCT04460508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF
Description: Pegylated rhG-CSF:6mg
Study NCT04460508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF
Description: rhG-CSF:5ug/kg/d
Study NCT04314648 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance Use Treatment and Recovery Team (START)
Description: Embedding of a collaborative care team, called the Substance Use Treatment and Recovery Team (START), for inpatients with OAUDs within an existing hospital consultation liaison psychiatry service.
Study NCT00003593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV
Study NCT01886196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug (Ibuprofen)
Description: 400mg of ibuprofen administered after exercise training session 3 days per week
Study NCT01886196 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: placebo designed to mimic experimental drug (ibuprofen)
Study NCT01886196 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo designed to mimic experimental drug (ibuprofen)
Study NCT01886196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo designed to mimic experimental drug (ibuprofen)
Study NCT01886196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: 3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym
Study NCT01886196 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance exercise
Description: 3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym
Study NCT01886196 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Flexibility training
Description: 3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised
Study NCT03859765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HCT Symptoms and Steps
Description: HCT Symptoms and Steps will provide patients with cognitive behavioral coping skills training and activity coaching sessions to enhance their ability to manage symptoms that interfere with activity.
Study NCT02929524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
Study NCT02929524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
Study NCT03832101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MATB
Description: MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention
Study NCT03832101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATB
Description: MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention
Study NCT01239134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRX518
Description: Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody
Study NCT01085123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapimelt
Description: oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.
Study NCT01085123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]AZ10419369
Description: solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
Study NCT00003593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT
Study NCT00003593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00003593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT04300517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Three sachet of protein supplement to be mixed in with water used daily
Description: Three sachet of protein supplement to be mixed in with water used daily
Study NCT03030495 — intervention group
Intervention type: DEVICE
Intervention: Comprehensive physiologic evaluation
Description: Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance
Study NCT03030495 — intervention group
Intervention type: DEVICE
Intervention: Intravascular imaging devices
Description: Intravascular ultrasound or optical coherence tomography
Study NCT00003593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT
Study NCT00003593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given IV
Study NCT01796990 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACT
Description: The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity.
Study NCT01796990 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: REF
Description: The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
Study NCT01796990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REF
Description: The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
Study NCT02511093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TBC intervention
Description: A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~* BP measurements;~* an educational and counselling intervention on patient adherence;~* an educational and counselling intervention on lifestyle (physical activity and diet) Physicians adjust antihypertensive medications based on nurse and pharmacist feedback.
Study NCT02497144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NMES Group
Description: Neuromuscular electrical stimulation
Study NCT02497144 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Breathing exercises
Study NCT04381949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positive pressure extubation
Description: Two arms:~the first with classic extubation with disconnection of the ventilator and the second with an extubation without disconnection of the respiratory positive pressure
Study NCT02246075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EVP-6124
Study NCT01506167 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab was administered as part of standard first-line treatment
Study NCT02246075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Study NCT02502461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cuff palpation
Description: Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
Study NCT02502461 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: cuff palpation
Description: Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
Study NCT01672333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOX
Description: oxaliplatin 100mg/m2 IV over 2 hours at 1st day docetaxel 50 mg/m2 IV over 1 hour at 1st day capecitabine 625 mg/m2 PO for 14 days
Study NCT01401790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telehomecare (Intelligent Distance Patient Monitoring)
Description: Randomized patients were to be taugth and to use for 3 months a telehomecare program designed for~* Automatic download of blood glucose levels~* Automatic alerts indicating hypoglycemias, hyperglycemias and ketones to the medical team~* Changes in treatment plan by the diabetes professionals~* E mail exchanges between families and health care professionals~* Reinforcement of teaching program
Study NCT01401790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard education and follow up at diabetes clinic
Description: Patients allocated to the control branch receive standard diabetes teaching and care.
Study NCT04011722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portico™ NG (Navitor) Valve and FlexNav™ Delivery System
Description: Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
Study NCT04011722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System
Description: Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
Study NCT05022446 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT03939715 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DermaPure®
Description: Surgical intervention using DermaPure®
Study NCT03939715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: native tissue
Description: Surgical intervention using native tissue
Study NCT01349777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregrel®
Description: Pregrel® 75mg daily for 12 months
Study NCT03516032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercises
Study NCT03524963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostan CR Tab.
Description: Cilostan CR Tab. 200mg once a day for 5 days
Study NCT03524963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pletaal SR Cap.
Description: Pletaal SR Cap. 200mg once a day for 5 days
Study NCT00771706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor
Description: The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
Study NCT00771706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
Study NCT01728558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early goal Directed Sedation